You are here: Industry Insights > leukemia

News List

Pharmaceutical News of the Week (July. 20th-July. 24th) | PharmaSources.com - Updates on R&D PharmaSources/Caicai
July 29, 2020
The hottest event of the week was the official kick-off of the centralized procurement of the third batch of pharmaceutical products organized in China, with 86 specifications started to be acquired the basic information.
FDA Approves Accelerated Dosing in Non-Hodgkin's Lymphoma/Leukemia Clinical Trial americanpharmaceuticalreview
July 14, 2021
AVM Biotechnology, a clinical-stage company, announced FDA permission to modify its ongoing non-Hodgkin's lymphoma/leukemia clinical study.
Using personalized medicine to avoid resistance to leukemia treatment worldpharmanews
May 11, 2021
T-cell acute lymphoblastic leukemia (T-ALL) is a very aggressive type of blood cancer. It is relatively rare but still draws a lot of attention as it mostly develops in children under the age of 20.
PRA Health Sciences, LLS Collaborate on Global Trial for Children with Acute Leukemia americanpharmaceuticalreview
September 07, 2020
The Leukemia & Lymphoma Society (LLS) and PRA Health Sciences has announced a partnership to launch a global master clinical trial to develop new treatments for children with relapsed acute leukemia.
Novartis’ ABL001 meets primary endpoint of phase 3 chronic myeloid leukemia study pharmaceutical-business-review
September 01, 2020
Novartis announced that, at primary analysis, the Phase III ASCEMBL study met its primary endpoint of statistically significant superiority in major molecular response (MMR) rate at 24 weeks for asciminib (ABL001) vs. bosutinib.
Vitamin B6, leukemia's deadly addiction worldpharmanews
January 14, 2020
Scientists have discovered that Acute Myeloid Leukemia (AML) grows by taking advantage of the B6 vitamin to accelerate cell division. The research team from Cold Spring Harbor Laboratory (CSHL) and ...
Rafael Expands CPI-613 Trial americanpharmaceuticalreview
December 27, 2019
Rafael Pharmaceuticals announced the expansion of its Phase 2 clinical trial of CPI-613® (devimistat) for patients with relapsed or refractory Burkitt’s lymphoma/leukemia.
Survival Up for Chronic Lymphocytic Leukemia 1995 to 2017 drugs
December 27, 2019
For patients with chronic lymphocytic leukemia (CLL) in routine care, overall survival improved from 1995 to 2017, according to a study recently published in Leukemia & Lymphoma.
Risk Score Developed to Help ID Heart Failure Risk in Leukemia drugs
December 20, 2019
In a study published in the December issue of JACC: CardioOncology, authors investigated the occurrence and developed a risk score to determine the risk for heart failure in patients with ...
Leukemia, lymphoma squarely in sights of new class of drugs worldpharmanews
December 09, 2019
UT Health San Antonio researchers, working with collaborators at the University of Florida, have discovered a safe and potent next generation of drugs to fight multiple types of ...

Previous page 1 2 3 4 5 Next page